In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.
In PLOS this week: links between placental transcriptome and weight; colorectal cancer-related microRNAs; and more.
Researchers are developing blood tests to determine people's chronotypes, according to Scientific American.
In Genome Biology this week: catalog of curated human genes and transcripts; potential biomarkers for aging; and more.
The finding could help detect autologous blood doping among athletes, Dark Daily reports.
The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.
The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.
The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
In PLOS this week: mutation linked to progressive ataxia in Charolais cattle, microRNA expression levels linked to colorectal cancer, and more.
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
